Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

• Main Authors: Christina Vasalou (Author), Theresa A. Proia (Author), Laura Kazlauskas (Author), Anna Przybyla (Author), Matthew Sung (Author), Srinivas Mamidi (Author), Kim Maratea (Author), Matthew Griffin (Author), Rebecca Sargeant (Author), Jelena Urosevic (Author), Anton I. Rosenbaum (Author), Jiaqi Yuan (Author), Krishna C. Aluri (Author), Diane Ramsden (Author), Niresh Hariparsad (Author), Rhys D.O. Jones (Author), Jerome T. Mettetal (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Trastuzumab deruxtecan (T‐DXd; DS‐8201; ENHERTU®) is a human epithelial growth factor receptor 2 (HER2)‐directed antibody drug conjugate (ADC) with demonstrated antitumor activity against a range of tumor types. Aiming to understand the relationship between antigen expression and downstream...